MEDNAX provides physician services including newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology and other pediatric subspecialty care. The company's network comprised of physicians, including physicians who provide neonatal clinical care, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications. The company also provides radiology services and teleradiology services. In addition to its national physician network, the company provides services to healthcare facilities and physicians, including the company's, through complementary businesses, consisting of a management services organization and a consulting services company.
  • TickerMD
  • ISINUS58502B1061
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

MEDNAX sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of MEDNAX (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date April 2, 2021, the closing price was USD 25.35 and its target price was estimated at USD 17.40.

Mednax Inc: 1 director sold

A director at Mednax Inc sold 100,000 shares at 25.403USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Moody's announces completion of a periodic review of ratings of MEDNAX, Inc.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of MEDNAX, Inc.. Global Credit Research- 14 Jan 2021. New York, January 14, 2021-- Moody's Investors Service has completed a periodic review of the ratings of MEDNAX, Inc. and other ratings that are associated with the same analytical unit.

MEDNAX, Inc.: Update to credit analysis following confirmation of rating with a positive outlook

MEDNAX's credit profile reflects its good liquidity and its strong competitive position in neonatology, against its moderately high leverage.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

• A number of Consumer Cyclical names continue to indicate leadership. (ex. THO, WGO, CROX, WLH, LEN, KBH, PZZA, TXRH, SCVL, GCO, and RH) • The Healthcare Sector has a number of attractive names developing major bases and staging RS reversals. (ex. CAH, HSIC, ITGR, ABT, MLAB, RMD, SYK, MD, RDNT, TRHC, CNC, WCG, RGNX, BEO, and SYNH) • The Technology Sector continues to be long-term leadership. Many issues are extended and we would suggest taking opportunity of any weakness. (ex. TER, AMAT, SYNA, INTC, AVGO, INTU, LPSN, CTXS, ADP, EXLS, PRSP, and FN)

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Mednax Inc: 1 director sold

A director at Mednax Inc sold 100,000 shares at 25.403USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Valens Research

UAFRS vs As Reported Weekly Highlights - 2020 11 19

This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for EL, MD, and VG.

MarketLine Department

Envision Healthcare Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Envision Healthcare Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Envision Healthcare Corp since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive ...

Moody's announces completion of a periodic review of ratings of MEDNAX, Inc.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of MEDNAX, Inc.. Global Credit Research- 14 Jan 2021. New York, January 14, 2021-- Moody's Investors Service has completed a periodic review of the ratings of MEDNAX, Inc. and other ratings that are associated with the same analytical unit.

MEDNAX, Inc.: Update to credit analysis following confirmation of rating with a positive outlook

MEDNAX's credit profile reflects its good liquidity and its strong competitive position in neonatology, against its moderately high leverage.

Moody's confirms MEDNAX's B1 CFR, outlook positive

Rating Action: Moody's confirms MEDNAX's B1 CFR, outlook positive. Global Credit Research- 18 Dec 2020. New York, December 18, 2020-- Moody's Investors Service confirmed MEDNAX, Inc.' s B1 Corporate Family Rating, the B1-PD Probability of Default Rating and the B1 unsecured global note ratings and changed the outlook to positive from rating under review.

MEDNAX, Inc.: Update following placement of ratings under review for upgrade

CORPORATES CREDIT OPINION 16 September 2020 Update RATINGS MEDNAX, Inc. Domicile Sunrise, Florida, United States Long Term Rating B1 , Possible Upgrade Type LT Corporate Family Ratings Outlook Rating(s) Under Review Please see the  ratings section  at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Kailas

Moody's places MEDNAX's ratings under review for upgrade

Rating Action: Moody's places MEDNAX's ratings under review for upgrade. Global Credit Research- 11 Sep 2020. New York, September 11, 2020-- Moody's Investors Service placed MEDNAX, Inc.' s B1 Corporate Family Rating, the B1-PD Probability of Default Rating and the B1 unsecured global note ratings on review for upgrade.

MEDNAX sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of MEDNAX (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date April 2, 2021, the closing price was USD 25.35 and its target price was estimated at USD 17.40.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch